top of page

BIO-Europe: Norway's Calluna Pharma was created over the last year through the combo of two co's going after the inflammatory and fibrotic spaces. The lead asset will advance to two phase 2s next year

  • blonca9
  • Nov 5, 2024
  • 1 min read

CEO Mark Gaffney describes the science behind the lead program, CAL101, which targets a Damage Associated Molecular Pattern protein called S100A4. It recently had P1 data in healthy volunteers and psoriasis patients, and will be advancing to two phase 2s in IPF and systemic sclerosis next year.



Brought to you by



Join the BiotechTV mailing list

Thanks for subscribing!

Follow BiotechTV

  • Twitter

@BiotechTV

  • LinkedIn

BiotechTV

  • Facebook

BiotechTVHQ

  • TikTok

@BiotechTV

  • Instagram

@BiotechTVHQ

Also look for unique social pages for BiotechTV U.

Sponsor Spotlight

HSBC_IB_Stacked_logo.png

HSBC Innovation Banking's dedicated sector experts possess in-depth knowledge of the technology, life science and healthcare economies. With access to an extensive global network, we can help you fuel growth through venture capital and corporate investors, industry influencers, customers, and global opportunities.

​

​Through our interconnected innovation hubs in the US, UK, Israel and Hong Kong, our experts are supporting the world’s innovation economy – both clients and their investors to help them meet their growth goals.

Learn more

bottom of page